| Diabetes Mellitus, Non-Insulin-Dependent
Januvia vs Soliqua
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Januvia vs Soliqua 100/33 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliqua 100/33 has a higher rate of injection site reactions vs Januvia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliqua 100/33 but not Januvia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Januvia
Soliqua 100/33
At A Glance
Oral
Once daily
DPP-4 inhibitor
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 100 mg orally once daily, with or without food.
Renal impairment (eGFR 30 to <45 mL/min/1.73 m2) 50 mg once daily.
Severe renal impairment or ESRD (eGFR <30 mL/min/1.73 m2) 25 mg once daily; may be administered without regard to the timing of dialysis.
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Contraindications
- History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema
- Hypoglycemia episodes
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, headache.
Serious Pancreatitis, heart failure, acute renal failure, hypoglycemia (with sulfonylurea or insulin), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid.
Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, acute pancreatitis, worsening renal function, acute renal failure, tubulointerstitial nephritis, severe arthralgia, bullous pemphigoid, constipation, vomiting, myalgia, pain in extremity, back pain, pruritus, mouth ulceration, stomatitis, rhabdomyolysis.
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Pharmacology
Sitagliptin is a DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon levels in a glucose-dependent manner; it is selective for DPP-4 and does not inhibit DPP-8 or DPP-9 activity at therapeutic concentrations.
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Januvia
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (12/12)
Soliqua 100/33
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
UnitedHealthcare
Januvia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Soliqua 100/33
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Januvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Soliqua 100/33
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Januvia.
No savings programs available for Soliqua 100/33.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JanuviaView full Januvia profile
Soliqua 100/33View full Soliqua 100/33 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.